[1] Harrington WJ, Minnich V, Hollingsworth JW, et al.Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura[J]. J Lab Clin Med, 1951, 38(1): 1-10. [2] Quach ME, Chen W, Li R.Mechanisms of platelet clearance and translation to improve platelet storage[J]. BLOOD, 2018, 131(14): 1512-1521. [3] Zheng SS, Ahmadi Z, Leung HHL, et al.Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia[J]. Haematologica, 2022, 107(9): 2195-2205. [4] Norris PAA, Tawhidi Z, Sachs UJ, et al.Serum from half of patients with immune thrombocytopenia trigger macrophage phagocytosis of platelets[J]. Blood Adv, 2023, 7(14): 3561-3572. [5] Olsson B, Andersson PO, Jernås M, et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J]. Nat Med, 2003, 9(9): 1123-1124. [6] Yan R, Chen M, Ma N, et al.Glycoprotein Ibα clustering induces macrophage-mediated platelet clearance in the liver[J]. Thromb Haemost, 2015, 113(1): 107-117. [7] Yang L, Wang L, Zhao CH, et al.Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia[J]. Blood, 2010, 116(20): 4307-4316. [8] Abbasi F, Kaydani GA, Tahannezhad Z, et al.Prevalence of Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Subclinical Infection in Patients with Acute Immune Thrombocytopenic Purpura (ITP)[J]. Int J Hematol Oncol Stem Cell Res, 2021, 15(3): 139-144. [9] Tsao HS, Chason HM, Fearon DM. Immune Thrombocytopenia (ITP) in a Pediatric Patient Positive for SARS-CoV-2[J]. Pediatrics, 2020, 146(2): e20201419. [10] Santhosh S, Malik B, Kalantary A, et al.Immune Thrombocytopenic Purpura (ITP) Following Natural COVID-19 Infection[J]. Cureus, 2022, 14(7): e26582. [11] Pezeshki SMS, Saki N, Ghandali MV, et al.Effect of Helicobacter Pylori eradication on patients with ITP: a meta-analysis of studies conducted in the Middle East[J]. Blood Res, 2021, 56(1): 38-43. [12] Li Q, Liu Y, Wang X, et al.Regulation of Th1/Th2 and Th17/Treg by pDC/mDC imbalance in primary immune thrombocytopenia[J]. Exp Biol Med, 2021, 246(15): 1688-1697. [13] Wu J, Wang ZT, Wang Q.Effect of Expression Level Changes of M-MDSC to Related Immune Function in Patients with Primary ITP[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2021, 29(2): 581-585. [14] Nie M, Liu Y, Li XX, et al.PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis[J]. Thromb Haemostasis, 2019, 119(5): 758-765. [15] Hua F, Li Y, Zhao X, et al.The expression profile of toll-like receptor signaling molecules in CD19(+) B cells from patients with primary immune thrombocytopenia[J]. Immunol Lett, 2016, 176: 28-35. [16] Deng G, Yu S, He Y, et al.MicroRNA profiling of platelets from immune thrombocytopenia and target gene prediction[J]. Mol Med Rep, 2017, 16(3): 2835-2843. [17] Sun Y, Hou Y, Meng G, et al.Proteomic analysis and microRNA expression profiling of plasma-derived exosomes in primary immune thrombocytopenia[J]. Brit J Haematol, 2021, 194(6): 1045-1052. [18] Zhu Y, Zhu H, Xie X, et al.MicroRNA expression profile in Treg cells in the course of primary immune thrombocytopenia[J]. J Invest Med, 2019, 67(8): 1118-1124. [19] He X, Wang T, Ran N, et al.MicroRNA-21-5p Regulates CD3+T Lymphocytes Through VCL and LTF in Patients with Immune Thrombocytopenia[J]. Clin Lab, 2022, 68(7):1355-1367. [20] Sun Y, Wang MJ, Cao XT, et al.Expression of MicroRNAs in Peripheral Blood of Patients with Primary Immune Thrombocytopenia and Its Correlation with the Imbalance of Th1/Th2 Cell[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2021, 29(5): 1570-1576. [21] Wang Y, Zhang J, Su Y, et al.miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia[J]. Mol Ther Nucleic Acids, 2020, 20: 764-776. [22] Wang Y, Guo Y, Zhang X, et al.The role and mechanism of miR-557 in inhibiting the differentiation and maturation of megakaryocytes in immune thrombocytopenia[J]. Rna Biol, 2021, 18(11): 1953-1968. [23] Wu XF, Li JQ, Hu SY, et al.Pathogenesis of Immune Thrombocytopenic Purpura (ITP) by MiRNA-30a-Mediated Th17 Cell Differentiation[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2020, 28(2): 588-594. [24] Smith TM Jr, Tharakan A, Martin RK.Targeting ADAM10 in Cancer and Autoimmunity[J]. Front Immunol, 2020, 11: 499. [25] Qiao J, Luo Q, Liu N, et al.Increased ADAM10 expression in patients with immune thrombocytopenia[J]. Int Immunopharmacol, 2017, 55: 63-68. [26] Korbecki J, Bajdak-Rusinek K, Kupnicka P, et al.The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases[J]. Int J Mol Sci, 2021, 22(7): 3490. [27] Hao Y, Li Y, Li H, et al.Increased plasma sCXCL16 levels may have a relationship with Th1/Th2 imbalance in primary immune thrombocytopenia[J]. Cytokine, 2017, 99: 124-131. [28] Bao N, Fu B, Zhong X, et al.Role of the CXCR6/CXCL16 axis in autoimmune diseases[J]. Int Immunopharmacol, 2023, 121: 110530. [29] Hassan AM, Farghal NMA, Hegab DS, et al.Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis[J]. Clin Rheumatol, 2018, 37(11): 3025-3032. [30] Isenberg JS, Roberts DD.THBS1 (thrombospondin-1)[J]. Atlas Genet Cytogenet Oncol Haematol, 2020, 24(8): 291-299. [31] Ye QD, Jiang H, Liao XL, et al.Identification and Validation of Gene Expression Pattern and Signature in Patients with Immune Thrombocytopenia[J]. Slas Discov, 2016, 22(2): 187-195. |